Opko Health Inc (OPK)

[tomsylver]

Rayaldee a Game Changer

Click Here ( http://www.veracast.com/webcasts/rbc/healthcare2015/24212400739.cfm ) to listen in full CEO Renal Division Charles W. Bishop discuss Rayaldee at the 2015 RBC Capital Markets’ Healthcare Conference.

Opko CEO Renal Division Charles W. Bishop, PhD

Five products in Phase 3. Host of products in earlier stage development. Top of the list is Rayaldee, a drug that has finished Phase 3 development. We will be submitting the NDA for Rayaldee next month. Rayaldee is a treatment for Secondary Hyperparathyroidism in patients who have pre-dialysis chronic kidney disease.

This product is going to be the first with the indication of treating Secondary Hyperparathyroidism that arises from Vitamin D Insufficiency in this patient population. No other product has this indication.

We think it will be a game changer for our pre-dialysis patients.

Rayaldee achieves Vitamin D sufficiency much more readily than any other product that is available. It lowers PTH as well as any product that is in the market. It does two things that Physician's want to do. Rayaldee allows Physician's to use one drug to get those two things done more effectively and safely.

Market for Rayaldee is large. Millions of patients that we target with Stage 3 & 4 CKD, one quarter are treated with active Vitamin D Hormones and one third are treated with Nutritional Vitamin D. Because neither of these options are very good about one half of the patient's are not treated at all. We believe Rayaldee can take share from all three of these categories and in fact expand the market.

With Rayaldee's target pricing at about $10,000 per year, you can see with every million patient's we have under treatment we will have a major financial opportunity.

"Rayaldee will be the only product in history with this indication." Charles W. Bishop, PhD